People: Catalyst Biosciences Inc (CBIO.OQ)
22 Jul 2019
De Souza, Errol
Dr. Errol B. De Souza, Ph.D. is Director of the company. He has been the president and chief executive officer of Biodel, a specialty pharmaceutical company, since March 2010. From April 2009 to March 2010, Dr. De Souza was a pharmaceutical and biotechnology consultant. From April 2003 to March 2009, he served as president and chief executive officer of Archemix Corporation, a privately held biopharmaceutical company. Dr. De Souza has served as president and chief executive officer of Synaptic Pharmaceutical Corp. until its sale to H. Lundbeck A/S. Dr. De Souza has served in key leadership roles such as senior vice president and head of global lead generation for Hoechst Marion Roussel and senior vice president and U.S. head of drug innovation and approval following that company’s merger with Rhône-Poulenc to form Aventis and co-founder and executive vice president of research and development at Neurocrine Biosciences, Inc. Dr. De Souza was a member of the board of directors of Targacept since January 2004 and became a member of the board of directors of Catalyst in August 2015. Dr. De Souza currently serves as a member of the board of directors of each of the publicly traded companies Biodel Inc. and Bionomics Ltd. In the past, Dr. De Souza has also served on boards of IDEXX Laboratories, Inc. and Palatin Technologies, Inc. Dr. De Souza received his B.A. in physiology and his Ph.D. in neuroendocrinology from the University of Toronto and he received his postdoctoral fellowship in neuroscience from The Johns Hopkins University School of Medicine.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|